Pharmacokinetics and pharmacodynamic effects of oral GLP-1 [glucagon-like-peptide-1] and PYY3-36 [peptide-YY-3-36]: a proof of concept study in healthy subjects

Trial Profile

Pharmacokinetics and pharmacodynamic effects of oral GLP-1 [glucagon-like-peptide-1] and PYY3-36 [peptide-YY-3-36]: a proof of concept study in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2007

At a glance

  • Drugs Peptide YY 3-36 (Primary) ; Glucagon-like peptide-1
  • Indications Diabetes mellitus; Heart failure; Obesity
  • Focus Pharmacokinetics
  • Most Recent Events

    • 11 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top